Vivos Therapeutics extends Streeterville deal to convert up to $4.5 million debt into equity

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOS

0.00
  • Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital through Aug. 31, 2026.
  • Streeterville reaffirmed plans to convert up to USD 4.5 million of debt into perpetual, non-convertible preferred stock, common stock.
  • Conversion starts once Vivos raises USD 2.6 million, continuing up to the USD 4.5 million cap.
  • Extension gives more time for an equity raise, supporting stockholders’ equity strength, Nasdaq continued listing compliance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220830PRIMZONEFULLFEED9750334) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.